Lilly lymphoma drug given exclusive status in Europe

March 26, 2007

The European Medicines Agency has granted Eli Lilly and Co.’s enzastaurin drug “orphan” status—a decade of marketing exclusivity for drugs aimed at serious, rare illnesses.

As a result, the Indianapolis drugmaker is ramping up a late-stage clinical trial of the oral agent, which is designed to limit relapses in patients with a type of non-Hodgkin’s lymphoma.

Separately, Bloomberg reports that Lilly plans to spend $150 million to triple the size of its research center in Singapore; a week earlier, the company said it would hire 100 extra sales people in Japan.

Source: XMLFULL/XMLFull1001.xml

Recent Articles by IBJ Staff

Comments powered by Disqus